Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has announced the successful exercise of warrants by an accredited investor, generating $4.7 million in gross proceeds for the company. This financial boost is aimed to support Lexaria’s working capital and general corporate endeavors, with new warrants also being issued at a premium that signifies investor confidence in the company’s future. The funds are expected to extend Lexaria’s operational capacity well into 2025, allowing for robust execution of the company’s plans for 2024.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
